Macdougall I C,Casadevall N,Locatelli F,et al.Incidence of erythropoietin antibody-mediated pure red cell aplasia:the Prospective Immunogenicity Surveillance Registry (PRIMS) [J].Nephrol Dial Transplant,2015,30(3):451-460.
[2]
Jacobs K,Shoemaker C,Rudersdorf R,et al.Isolation and characterization of genomic and cDNA clones of human erythropoietin[J].Nature,1985,313(28):806-810.
[3]
Sulikowska B,Johnson R J,Wiechecka K J,et al.Dopamine-induced changes in serum erythropoietin and creatinine clearance reflect risk factors for progression of IgA nephropathy[J].J Investig Med,2015,63(6):811-815.
[4]
Teixeira Am,Garrido P,Santos P,et al.Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure[J].Ren Fail, 2010,3 2(9):1073-1080.
[5]
Zhang F,Xing J,Liou Ak,et al.Enhanced delivery of erythropoietin across the blood-brain barrier for neuroprotection against ischbemic neuronal injury[J]. Transl Stroke Res,2010,1(2):113-121.
[6]
Willem G,Gertrude J,Petra J,et al.Renoprotective capacities of non-erythropoietic EPO derivative,ARA290,following renal ischemia/reperfusion injury [J]. Transl Med, 2013,11(1):289-293.
[7]
Ruggero D,Shimamura A.Marrow fai lure:a window into ribosome biology[J].Blood,2014,124(18):2784-2792.
[8]
Hirokawa M,Progress in the clinical management of pure red cell aplasia and future prospects[J].Rinsho Ketsueki,2016,57(2):110-116.
Ikawa Y,Nishimura R,et al,Kuroda R,et al.Expansion of a liver-infiltrating cytotoxic T-lymphocyte clone in concert with the development of hepatitis-associated aplastic anemia[J].B r J Haematol,2013,161(4):599-602.
[12]
Kordasti S,Marsh J,Alkhan S,et al.Functional characterization of CD4+T cells in aplastic anemia[J].Blood,2012,9(9):335-337.
Macdougall I C,Roger S D, Francisco A,et al.Antibody mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents:new insights[J].Kidney Int,2012,81(8):727-732.
[15]
Hermeling S,Schellekens H,Crommcelin D J,et al.Micelle-as- sociated protein in epoetin formulations:A risk factor for immunogenicity[J]. Pharm Res,2013,20(12):1903-1907.
[16]
Horl W H.Differentiating factors between erythropoiesis stimulating agent:an update to selection for anaemia of chronic kidney disease [J].Drugs,2013,73(2):117-130.
[17]
Slominski A,Zjawiony J,Wortsman J,et al.A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin[J].Eur J Biochem,2004,271(21):4178-4188.
[18]
Verhelst D,Rossert J,Casadevall N,et al.Treatment of antibody-mediated pure red cell aplasia:a retrospective study[J].Lancet,2004,363:1768-1771.
Aoki k,Ono Y,Tabata S,et al.Successful treatment of anti-erythropoietin antibody mediated pure red cell aplasia with low-dose prednisolone[J].Int J Hematol,2013,97(2):272-274.
[21]
Hirokawa M,Sawada K,Fujishima N,et al.Long-term outcome of patients with acquired chronic pure red cell aplasia(PRCA) following immunosuppressive therapy:a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group[J].Br J Haematol,2015,169(6):879- 886.
[22]
Maxwell P H,Eckardt K U.HIF prolyl hydroxylase inhibitors for treatment of renal anaemia and beyond[J].Nat Rev Nephrol,2016,12(3):99-105.
[23]
Koury M J,Haase V H.Anaemia in kidney disease:harnessing hypoxia responses for therapy[J].Nat Rev Nephrol,2015,11(7):394-410.
[24]
Fishbane S, Roger S D, Martin E, et al. Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa[J]. Clin J Am Soc Nephrol, 2013, 8(4): 538-545.
2018, Vol. 29 
